Magnetic Resonance Imaging-based T-staging to Predict Biochemical Recurrence after Radical Prostatectomy: A Step Towards the iTNM Classification.


Journal

European urology oncology
ISSN: 2588-9311
Titre abrégé: Eur Urol Oncol
Pays: Netherlands
ID NLM: 101724904

Informations de publication

Date de publication:
08 2023
Historique:
received: 01 07 2022
revised: 13 09 2022
accepted: 30 09 2022
medline: 31 7 2023
pubmed: 25 10 2022
entrez: 24 10 2022
Statut: ppublish

Résumé

Local staging of prostate cancer (PCa) still relies on digital rectal examination (DRE), which therefore remains the standard for risk stratification in guideline recommendations, clinical trials, and patient counseling. This issue is increasingly controversial as multiparametric magnetic resonance imaging (mpMRI) has become the most influential diagnostic tool for local staging of PCa over the past two decades. To compare various models of T category based on DRE or mpMRI to predict early biochemical recurrence (BCR) after radical prostatectomy (RP). A retrospective multicenter cohort study was conducted between 2014 and 2021. A total of 1436 patients were recruited across eight referral centers in France, Italy, Switzerland, and Belgium. BCR was defined as two prostate-specific antigen values of ≥0.2 ng/ml during follow-up. Harrell's concordance index (C index) was used to compare the discrimination of four models of T staging based on DRE (model 1: cT1 vs cT2 vs cT3) or mpMRI (model 2: organ-confined disease vs extracapsular extension [iECE] vs seminal vesicle invasion [iSVI]; model 3: Prostate Imaging-Reporting and Data System [PI-RADS] ≤3 vs PI-RADS 4 vs PI-RADS 5; and model 4: iT2a [PI-RADS ≤3] vs iT2b [PI-RADS 4] vs iT2c [PI-RADS 5 excluding ECE or SVI] vs iT3a [ECE] vs iT3b [SVI]) to predict BCR. Overall, 74 (5%), 845 (59%), 482 (34%), and 35 (2%) patients had low-, intermediate-, high-, and very high-risk PCa, respectively, according to the Mazzone risk classification. After median follow-up of 16 mo, 113 patients experienced BCR. Although the new five-group mpMRI-based T classification system (model 4) had the highest prognostic discrimination (C index 0.694) for predicting early BCR on multivariable analysis, there was overlap between the 95% confidence intervals of the models. On sensitivity analysis, the new mpMRI-based T staging still had a higher C index than DRE for predicting BCR when excluding cN1 patients and comparing it with a five-group DRE-based T classification (cT1c vs cT2a vs cT2b vs cT2c vs cT3), but the overlap between the 95% confidence intervals of the models remained. The main limitation is the short follow-up. We described an alternative mpMRI-based T staging for prediction of early BCR after RP for PCa. Our results need to be validated externally before they can be applied in clinical practice. At present, digital rectal examination of the prostate is used to stage prostate cancer. We developed an alternative model for staging that uses information from magnetic resonance imaging (MRI) scans to predict cancer outcomes for men undergoing surgical removal of the prostate.

Sections du résumé

BACKGROUND
Local staging of prostate cancer (PCa) still relies on digital rectal examination (DRE), which therefore remains the standard for risk stratification in guideline recommendations, clinical trials, and patient counseling. This issue is increasingly controversial as multiparametric magnetic resonance imaging (mpMRI) has become the most influential diagnostic tool for local staging of PCa over the past two decades.
OBJECTIVE
To compare various models of T category based on DRE or mpMRI to predict early biochemical recurrence (BCR) after radical prostatectomy (RP).
DESIGN, SETTING, AND PARTICIPANTS
A retrospective multicenter cohort study was conducted between 2014 and 2021. A total of 1436 patients were recruited across eight referral centers in France, Italy, Switzerland, and Belgium.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS
BCR was defined as two prostate-specific antigen values of ≥0.2 ng/ml during follow-up. Harrell's concordance index (C index) was used to compare the discrimination of four models of T staging based on DRE (model 1: cT1 vs cT2 vs cT3) or mpMRI (model 2: organ-confined disease vs extracapsular extension [iECE] vs seminal vesicle invasion [iSVI]; model 3: Prostate Imaging-Reporting and Data System [PI-RADS] ≤3 vs PI-RADS 4 vs PI-RADS 5; and model 4: iT2a [PI-RADS ≤3] vs iT2b [PI-RADS 4] vs iT2c [PI-RADS 5 excluding ECE or SVI] vs iT3a [ECE] vs iT3b [SVI]) to predict BCR.
RESULTS AND LIMITATIONS
Overall, 74 (5%), 845 (59%), 482 (34%), and 35 (2%) patients had low-, intermediate-, high-, and very high-risk PCa, respectively, according to the Mazzone risk classification. After median follow-up of 16 mo, 113 patients experienced BCR. Although the new five-group mpMRI-based T classification system (model 4) had the highest prognostic discrimination (C index 0.694) for predicting early BCR on multivariable analysis, there was overlap between the 95% confidence intervals of the models. On sensitivity analysis, the new mpMRI-based T staging still had a higher C index than DRE for predicting BCR when excluding cN1 patients and comparing it with a five-group DRE-based T classification (cT1c vs cT2a vs cT2b vs cT2c vs cT3), but the overlap between the 95% confidence intervals of the models remained. The main limitation is the short follow-up.
CONCLUSIONS
We described an alternative mpMRI-based T staging for prediction of early BCR after RP for PCa. Our results need to be validated externally before they can be applied in clinical practice.
PATIENT SUMMARY
At present, digital rectal examination of the prostate is used to stage prostate cancer. We developed an alternative model for staging that uses information from magnetic resonance imaging (MRI) scans to predict cancer outcomes for men undergoing surgical removal of the prostate.

Identifiants

pubmed: 36280445
pii: S2588-9311(22)00169-9
doi: 10.1016/j.euo.2022.09.005
pii:
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

406-413

Informations de copyright

Copyright © 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Michael Baboudjian (M)

Department of Urology, La Croix du Sud Hôpital, Quint Fonsegrives, France; Department of Urology, North Hospital, Aix-Marseille University, APHM, Marseille, France; Department of Urology, La Conception Hospital, Aix-Marseille University, APHM, Marseille, France; Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, Barcelona, Spain. Electronic address: michael.baboudjian@outlook.fr.

Bastien Gondran-Tellier (B)

Department of Urology, La Conception Hospital, Aix-Marseille University, APHM, Marseille, France.

Alae Touzani (A)

Department of Urology, La Croix du Sud Hôpital, Quint Fonsegrives, France.

Alberto Martini (A)

Department of Urology, La Croix du Sud Hôpital, Quint Fonsegrives, France.

Romain Diamand (R)

Department of Urology, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.

Jean-Baptiste Roche (JB)

Urology Department, Clinique Saint-Augustin, Bordeaux, France.

Vito Lacetera (V)

Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, Italy.

Jean-Baptiste Beauval (JB)

Department of Urology, La Croix du Sud Hôpital, Quint Fonsegrives, France.

Thierry Roumeguère (T)

Department of Urology, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.

Guiseppe Simone (G)

Department of Urology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Daniel Benamran (D)

Division of Urology, Geneva University Hospitals, Geneva, Switzerland.

Alexandre Fourcade (A)

Department of Urology, Hôpital Cavale Blanche, CHRU Brest, Brest, France.

Gaelle Fiard (G)

Department of Urology, Grenoble Alpes University Hospital, Université Grenoble Alpes, CNRS, Grenoble INP, TIMC, Grenoble, France.

Roderick C N van den Bergh (RCN)

Department of Urology, St. Antonius Hospital, Utrecht, The Netherlands.

Alexandre Peltier (A)

Department of Urology, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.

Guillaume Ploussard (G)

Department of Urology, La Croix du Sud Hôpital, Quint Fonsegrives, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH